The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) is a huge mover today! About 1.80 million shares traded hands or 816.70% up from the average. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 19.64% since April 18, 2016 and is uptrending. It has outperformed by 15.21% the S&P500.
The move comes after 5 months positive chart setup for the $581.49 million company. It was reported on Nov, 18 by Barchart.com. We have $38.22 PT which if reached, will make NASDAQ:ACRS worth $284.93M more.
Aclaris Therapeutics Inc (NASDAQ:ACRS) Ratings Coverage
Out of 4 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Aclaris Therapeutics has been the topic of 8 analyst reports since November 2, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Jefferies on Monday, September 19. Guggenheim initiated the shares of ACRS in a report on Friday, June 10 with “Buy” rating. The stock has “Buy” rating given by Jefferies on Monday, November 2. The firm has “Buy” rating given on Monday, November 2 by Citigroup. The rating was maintained by Jefferies with “Buy” on Friday, August 12. As per Monday, November 2, the company rating was initiated by William Blair. JMP Securities initiated the shares of ACRS in a report on Friday, September 30 with “Market Perform” rating.
According to Zacks Investment Research, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.”
More recent Aclaris Therapeutics Inc (NASDAQ:ACRS) news were published by: Foxbusiness.com which released: “Why Aclaris Therapeutics, Inc. Stock Is Down Today” on November 17, 2016. Also Investorplace.com published the news titled: “3 Stocks to Watch on Wednesday: Aclaris Therapeutics Inc (ACRS), Agilent …” on November 16, 2016. Streetinsider.com‘s news article titled: “Aclaris Therapeutics (ACRS) Prices 4M Stock Offering at $22.75/Share” with publication date: November 18, 2016 was also an interesting one.
ACRS Company Profile
Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.